The box office momentum is real, and 2026's film slate shows genuine artistic range alongside commercial performance. Variety's midyear assessment catches the industry at an inflection point where blockbuster health and prestige filmmaking are moving in tandem rather than competing for oxygen.
This matters because 2025 left Hollywood bruised. The combination of streaming cannibalization, franchise fatigue, and AI anxieties created a malaise that rippled through production slates and theatrical strategies alike. What Variety identifies as a midyear temperature check reveals something studios needed: evidence that audiences still want movies on the biggest screens, for the biggest experiences, and that those same audiences haven't abandoned smaller, character-driven work.
The box office uptick signals that marketing departments finally cracked something about what moviegoers want post-pandemic. It's not just spectacle. It's event films paired with the kind of original storytelling that can't stream first. The diversity of what's working suggests the industry is moving beyond the reductive "franchise or die" calculus that dominated 2023 and 2024.
What's equally telling is that this resurgence doesn't require choosing sides. The films stacking up in 2026's second half appear to span the register. Studios are greenlighting prestige directors for mid-budget productions while simultaneously treating IP with more craft. Actors are choosing projects based on script quality rather than just paycheck size. That shift costs money upfront but creates the kind of word-of-mouth that actually moves tickets.
The caveat Variety wisely includes is real. You cannot fully evaluate a year halfway through. September brings festival season and awards season posturing. October signals Oscar ambitions. The back half of 2026 will determine whether this health is sustainable or a temporary bounce before another contraction. But the baseline fact remains: six months in, the business looks